AstraZeneca Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
February 19 2018 - 02:51AM
Dow Jones News
By Dimitrios Kontos
AstraZeneca PLC (AZN.LN) said Monday that Imfinzi has received
the approval of the U.S. Food and Drug Administration for the
treatment of patients with a form of cell lung cancer.
Imfinzi is the only immunotherapy approved for patients with
Stage 3 non-small cell lung cancer that cannot be removed via
surgery, the London-listed pharmaceutical company said.
The approval is based on the study's results, which showed that
Imfinzi can help prolong patients' lives, the company said.
The company also said until Imfinzi, patients had no
FDA-approved treatment options after chemoradiation therapy.
Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com
(END) Dow Jones Newswires
February 19, 2018 02:36 ET (07:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024